Results 101 to 110 of about 265 (150)

Pharmacokinetics of Miocamycin in Patients with Liver Cirrhosis

Chemotherapy, 1989
The pharmacokinetics of miocamycin, a new macrolide antibiotic, was studied in 6 healthy controls and 6 patients with compensated liver cirrhosis. The results indicate that in chronic liver disease the kinetics of the drug is altered. Therefore, a dosage adjustment of miocamycin is recommended when dealing with these patients.
Miglioli PA, Pivetta P, ORLANDO, ROCCO, PALATINI, PIETRO, Varotto A, Okolicsanyi L.   +5 more
openaire   +3 more sources

Miocamycin

Drugs, 1993
Miocamycin is an orally administered 16-membered macrolide antimicrobial drug. It has a spectrum of in vitro activity similar to that of erythromycin, inhibiting a range of Gram-positive and Gram-negative organisms, atypical microbes and some anaerobes.
S M, Holliday, D, Faulds
openaire   +2 more sources

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-10. Toxicity of metabolites of miocamycin: acute toxicity of Mb12 in mice.

The Japanese journal of antibiotics, 1985
We evaluated acute toxicity and estimated LD50 values of Mb12, one of the main metabolites of MOM, in male and female mice after single oral administration. Observations were continued for 1 week after treatment. The LD50 values were calculated according to Litchfield-Wilcoxon's method. It is concluded that LD50 values of Mb12 were 5,750 mg/kg (4,914.5-
M, Yokota, U, Takeda, M, Odaki, H, Sasaki, H, Kawaoto, T, Itoh, T, Koeda   +6 more
openaire   +5 more sources

Clinical efficacy of dirithromycin versus miocamycin in tonsillopharyngitis

Journal of Antimicrobial Chemotherapy, 1993
A single-blind, randomized, parallel-group study was conducted to compare the efficacy and safety of dirithromycin with miocamycin in the treatment of streptococcal pharyngitis/tonsillitis caused by Group A streptococci. The study population consisted of 60 patients: 30 were randomized to receive 500 mg dirithromycin od and 30 to receive 600 mg ...
RUGGIERO G, UTILI, Riccardo, ADINOLFI, Luigi Elio, ATTANASIO V, SCARANO MP, MAZZONE, Adriano, COSTA, Giuseppe, CALIFANO L, COSTA F.   +8 more
openaire   +3 more sources

Miocamycin‐Containing Triple Therapy for H. pylori Infection

Helicobacter, 2013
AbstractIntroductionIn Northern Sardinia, one‐week triple standard therapies containing a proton‐pump inhibitor and two antibiotics for H. pylori infection have an average cure rate of 57% largely due to a high prevalence of antimicrobial resistance. The efficacy of miocamycin‐containing treatment for 10 days was evaluated.Materials and MethodsPatients
Maria Pina Dore, Marco Massidda, Ozlem Yilmaz, Ebru Demiray G?rb?z, Alessandra Manca, BASSOTTI, GABRIO   +5 more
openaire   +5 more sources

Miocamycin and theophylline blood levels.

Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986
Two groups of patients were studied in order to evaluate the possible interference of miocamycin with theophylline blood levels. One group was treated with i.v. theophylline and another one was treated with slow-release theophylline. Both groups did not show any changes in theophylline blood levels. Therefore we can draw the conclusion that miocamycin,
R, Rimoldi, M, Bandera, M, Fioretti, R, Giorcelli   +3 more
openaire   +1 more source

In- VitroPostantibiotic Effects of Miocamycin and Erythromycin on Gram-Positive Cocci

Journal of Chemotherapy, 1990
The capability of miocamycin to induce a postantibiotic effect (PAE) on a Group A Streptococcus beta-haemolyticus clinical isolate and on Staphylococcus aureus ATCC 29213 has been studied. Erythromycin was chosen as a reference molecule. The exposure time to antibiotics was 90 min.
F, Varotto, M L, Garlaschi, M C, Garlaschi, M, Falchi, F, Scaglione, G, Cattaneo, M, De Luca, F, Fraschini   +7 more
openaire   +2 more sources

Anti-mycoplasmal activity of a new macrolide: miocamycin.

Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1987
The object of this study was the evaluation of the activity of miocamycin and other macrolides (erythromycin and josamycin) against 61 Ureaplasma urealyticum, 1 Acholeplasma laidlawii and 21 aerobe mycoplasmas (M. pneumoniae, M. hominis, M. gallisepticum, M. mycoides) and anaerobe mycoplasmas (M. morale and M.
FURNERI, Pio Maria, TEMPERA G, BISIGNANO G, COTTARELLI FV, NICOLETTI G.   +4 more
openaire   +3 more sources

Streptococcal pharyngitis in Italian children: epidemiology and treatment with miocamycin.

Drugs under experimental and clinical research, 1990
A prospective multicentre study of Italian children with acute pharyngotonsillitis was carried out to determine the incidence of beta-haemolytic streptococcal infection and its epidemiological characteristics and to evaluate the effectiveness of a recently marketed macrolide, miocamycin.
N. Principi, P. Marchisio, A. Calanchi, J. Onorato, A. Plebani, E. Reali, L. Rancilio, E. Grasso, L. Magni, G. Caramia   +9 more
openaire   +4 more sources

[Use of miocamycin in infections of the oral cavity].

Minerva stomatologica, 1989
The results of clinical experimental with a new antibiotic, Miocamycin (Macroral Zambeletti), are reported. 300 patients suffering from the most varied infections of the oral cavity were treated. In view of its utility and the lack of side-effects, it is concluded that this antibiotic may be used with peace of mind in odontostomatological pathology.
F, Fiorentini, E, D'Alessandri
openaire   +1 more source